1. Home
  2. CURB vs IBRX Comparison

CURB vs IBRX Comparison

Compare CURB & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CURB
  • IBRX
  • Stock Information
  • Founded
  • CURB 2024
  • IBRX 2014
  • Country
  • CURB United States
  • IBRX United States
  • Employees
  • CURB N/A
  • IBRX N/A
  • Industry
  • CURB
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CURB
  • IBRX Health Care
  • Exchange
  • CURB NYSE
  • IBRX Nasdaq
  • Market Cap
  • CURB 2.5B
  • IBRX 2.4B
  • IPO Year
  • CURB N/A
  • IBRX N/A
  • Fundamental
  • Price
  • CURB $23.77
  • IBRX $4.49
  • Analyst Decision
  • CURB Buy
  • IBRX Buy
  • Analyst Count
  • CURB 5
  • IBRX 2
  • Target Price
  • CURB $25.69
  • IBRX $17.38
  • AVG Volume (30 Days)
  • CURB 548.9K
  • IBRX 10.4M
  • Earning Date
  • CURB 11-22-2024
  • IBRX 11-12-2024
  • Dividend Yield
  • CURB N/A
  • IBRX N/A
  • EPS Growth
  • CURB N/A
  • IBRX N/A
  • EPS
  • CURB 0.06
  • IBRX N/A
  • Revenue
  • CURB $111,428,000.00
  • IBRX $7,332,000.00
  • Revenue This Year
  • CURB N/A
  • IBRX $1,563.18
  • Revenue Next Year
  • CURB N/A
  • IBRX $1,262.20
  • P/E Ratio
  • CURB $388.04
  • IBRX N/A
  • Revenue Growth
  • CURB 52.36
  • IBRX 1218.71
  • 52 Week Low
  • CURB $18.80
  • IBRX $3.10
  • 52 Week High
  • CURB $25.15
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • CURB N/A
  • IBRX 46.07
  • Support Level
  • CURB N/A
  • IBRX $4.57
  • Resistance Level
  • CURB N/A
  • IBRX $5.08
  • Average True Range (ATR)
  • CURB 0.00
  • IBRX 0.54
  • MACD
  • CURB 0.00
  • IBRX -0.12
  • Stochastic Oscillator
  • CURB 0.00
  • IBRX 3.16

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Share on Social Networks: